Cardiovascular Events From Trifluridine/Tipiracil +/- Oxaliplatin in Colorectal/Oesogastric Adenocarcinoma Patients
Status:
Recruiting
Trial end date:
2025-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess of incidence of cardiovascular events in patients with
esophageal/stomach or colorectal cancer treated by trifluridine/tipiracil +/- oxaliplatin
after an episode of cardiac angina-related thoracic pain in the adjuvant, or metastatic
setting due to fluoropyrimidines
Phase:
Phase 2
Details
Lead Sponsor:
GERCOR - Multidisciplinary Oncology Cooperative Group